Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) EBITDA (2016 - 2025)

Kiora Pharmaceuticals' EBITDA history spans 11 years, with the latest figure at -$6.5 million for Q4 2025.

  • For Q4 2025, EBITDA fell 47.14% year-over-year to -$6.5 million; the TTM value through Dec 2025 reached -$10.8 million, down 408.95%, while the annual FY2025 figure was -$10.8 million, 408.95% down from the prior year.
  • EBITDA reached -$6.5 million in Q4 2025 per KPRX's latest filing, down from $28867.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $13.4 million in Q1 2024 to a low of -$6.5 million in Q4 2025.
  • Average EBITDA over 5 years is -$2.4 million, with a median of -$2.6 million recorded in 2023.
  • Peak YoY movement for EBITDA: tumbled 374.34% in 2021, then soared 803.32% in 2024.
  • A 5-year view of EBITDA shows it stood at -$6.2 million in 2021, then rose by 16.93% to -$5.2 million in 2022, then surged by 57.63% to -$2.2 million in 2023, then plummeted by 102.74% to -$4.4 million in 2024, then plummeted by 47.14% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's EBITDA are -$6.5 million (Q4 2025), $28867.0 (Q3 2025), and -$2.1 million (Q2 2025).